| 0.0701 0 (0%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.11  |
1-year : | 0.16 |
| Resists | First : | 0.1 |
Second : | 0.13 |
| Pivot price | 0.05  |
|||
| Supports | First : | 0.04 |
Second : | 0.03 |
| MAs | MA(5) : | 0.04 |
MA(20) : | 0.06 |
| MA(100) : | 0.59 |
MA(250) : | 1.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.1 |
D(3) : | 4.5 |
| RSI | RSI(14): 32 |
|||
| 52-week | High : | 2.7 | Low : | 0.04 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PHAS ] has closed above bottom band by 38.0%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.05 - 0.05 | 0.05 - 0.05 |
| Low: | 0.04 - 0.04 | 0.04 - 0.04 |
| Close: | 0.05 - 0.05 | 0.05 - 0.05 |
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Mon, 12 May 2025
Uncontrolled Bleeding Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - The Globe and Mail
Mon, 20 Jan 2025
Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire
Thu, 26 Dec 2024
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender - MedCity News
Fri, 12 Jul 2024
PhaseBio announces bankruptcy plan confirmation - Investing.com
Mon, 24 Oct 2022
PhaseBio Files for Bankruptcy, Inks Deal to Sell Assets to Unnamed Company (Updated) - BioSpace
Mon, 15 Nov 2021
Form 8-K PhaseBio Pharmaceuticals For: Nov 15 - StreetInsider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 3.441e+007 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 1,470 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0226e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -12 % |
| Return on Assets (ttm) | 738.6 % |
| Return on Equity (ttm) | -106.1 % |
| Qtrly Rev. Growth | 818000 % |
| Gross Profit (p.s.) | -34.15 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.18049e+007 |
| Qtrly Earnings Growth | -2.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.06 |
| Dividend | 0 |
| Forward Dividend | 2.07e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|